Screener
Artiva Biotherapeutics, Inc. ARTV Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
| Line item | SIX MONTHS ENDED JUNE 30, 2026 | SIX MONTHS ENDED JUNE 30, 2025 |
|---|---|---|
| Proceeds from purchase of ESPP shares | 138 | 134 |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | (210) | (39) |
| Payments on finance leases | (45) | (66) |
| Net cash provided by financing activities | 283,157 | 167 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 274,753 | (11,564) |
| Cash, cash equivalents and restricted cash at beginning of period | 27,162 | 40,493 |
| Cash, cash equivalents and restricted cash at end of period | $301,915 | $28,929 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet: |
Item 1. Financial Statements
FAQ
- What is Artiva Biotherapeutics, Inc.'s financing cash flow?
- Artiva Biotherapeutics, Inc. (ARTV) reported financing cash flow of $283.27M in Q2 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Artiva Biotherapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude